Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 9476Triple Negative Breast Neoplasms 635Neoplasms 413Lung Neoplasms 342Prostatic Neoplasms 321Ovarian Neoplasms 299Colorectal Neoplasms 289Neoplasm Metastasis 280Motor Activity 267Carcinoma, Intraductal, Noninfiltrating 231Colonic Neoplasms 193Breast Neoplasms, Male 172Lymphedema 170Melanoma 158Pancreatic Neoplasms 152Breast Carcinoma In Situ 151Carcinoma, Non-Small-Cell Lung 149Uterine Cervical Neoplasms 144Fatigue 140Head and Neck Neoplasms 132Pain 122Breast Cancer Female 122Brain Neoplasms 118Stomach Neoplasms 117Sarcoma 106Depression 105Breast Cancer Lymphedema 101Anxiety Disorders 101Lymphoma 96Cardiotoxicity 89

Interventions

ixabepilone 1Standard of Care 1Practice Guidelines as Topic 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Bilateral Breast Carcinoma × Breast × Clear all
NCT00877500 2026-05-22

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
116 enrolled
Breast

Bilateral Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡